Inhaled ED drug tested for safety in healthy people

NCT ID NCT05567367

Completed Knowledge-focused Sponsor: Respira Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-phase trial tested the safety and how the body processes an inhaled form of vardenafil (RT234) in 31 healthy adults. Participants received single and multiple doses of the drug via an inhaler or as a pill. The study is complete and focused on side effects and drug levels, not on treating any disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RT234 (vardenafil inhalation powder)

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiovascular disorder Familial Primary Pulmonary Hypertension lung disorder pulmonary arterial hypertension pulmonary hypertension respiratory system disorder vascular disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEER

Contacts and locations

Locations

Nucleus Network, Burnet Institute

Prahran, Victoria, 3004, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.